Selexis Featured in: Technology (Special Issues on BioAlps)
November 26, 2018
Selexis is driving innovation in cell line development from research to manufacturing. Headquartered in Geneva, Switzerland, Selexis is the global leader in cell line development that enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines, including therapeutics that help...
Learn More
Drug Discovery News Special Report: Well CHOsen?
November 4, 2018
Special Report on Cell Biology Well CHOsen? Ever-more complicated biologics push technical boundaries By Randall C Willis “Increasingly, we see scientists addressing complicated and intractable diseases by developing complex protein therapeutics such as bi- and tri-specific proteins, DARPins, triabodies, novel scaffolds decorated with peptides, enzymes...
Learn More
Obtaining the Optimal Clone: Exploiting metabolic selection in mammalian cells for clonal enrichment, particularly for difficult-to-express proteins.
November 21, 2017
The life sciences industry is increasingly addressing lifethreatening diseases with sophisticated and complex protein therapeutics, such as novel scaffolds, fusion proteins, bi-specific proteins, and cytotoxic cytokines and interferons. These next-generation therapeutics, which are often difficult-to-express proteins, have been accompanied by a new set of challenges...
Learn More
Making the Right Choice: Transient vs. Stable Pool Expression in CHO Cells
September 29, 2017
Historically, transient and stable transfections have been performed for different purposes. Transient transfections can rapidly provide reasonable amounts of recombinant proteins (mg quantities) for early evaluation of their activity and typically transient transfections were used in the screening stages of a project when potential clinical...
Learn More